GNLX
Genelux Corporation NASDAQ Listed Jan 26, 2023$2.90
After hrs
$2.90
+0.00%
Mkt Cap $107.8M
52w Low $2.30
10.1% of range
52w High $8.24
50d MA $2.88
200d MA $3.70
P/E (TTM)
-3.3x
EV/EBITDA
—
P/B
9.3x
Debt/Equity
0.1x
ROE
-278.5%
P/FCF
-4.1x
RSI (14)
52.20
ATR (14)
$0.18
Beta
0.46
50d MA
$2.88
200d MA
$3.70
Avg Volume
174.9K
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
2625 Townsgate Road · Westlake Village, CA 91361 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.22 | -0.24 | -9.1% | 2.54 | -5.5% | -5.5% | +3.3% | -2.4% | +9.5% | -0.8% | — |
| Nov 5, 2025 | AMC | -0.23 | -0.21 | +8.7% | 7.84 | -4.3% | -32.4% | +2.3% | +8.7% | +1.5% | -0.8% | — |
| Aug 7, 2025 | AMC | -0.22 | -0.20 | +9.1% | 3.34 | +6.6% | -5.7% | +4.1% | -2.7% | +0.3% | +6.6% | — |
| May 6, 2025 | AMC | -0.24 | -0.21 | +12.5% | 2.33 | +2.6% | -0.4% | +22.8% | +3.9% | -6.1% | -10.8% | — |
| Mar 28, 2025 | AMC | -0.17 | -0.26 | -52.9% | 3.08 | -2.6% | -12.3% | -3.7% | -2.3% | -1.6% | -4.4% | — |
| Nov 14, 2024 | AMC | -0.19 | -0.19 | +0.0% | 2.94 | +0.0% | -19.7% | +11.4% | -5.7% | +0.4% | -1.2% | — |
| Aug 14, 2024 | AMC | -0.19 | -0.22 | -15.8% | 2.09 | +4.3% | +1.9% | -5.2% | +3.5% | -2.4% | +0.5% | — |
| May 9, 2024 | AMC | -0.23 | -0.29 | -26.1% | 4.02 | -1.5% | -4.7% | -5.7% | -0.8% | +1.7% | -1.1% | — |
| Mar 29, 2024 | AMC | -0.21 | -0.25 | -19.0% | — | — | — | — | — | — | — | — |
| Nov 14, 2023 | AMC | -0.12 | -0.20 | -66.7% | 14.59 | -3.4% | -7.6% | -2.7% | -9.5% | -9.7% | -3.2% | — |
| Aug 14, 2023 | AMC | -0.15 | -0.23 | -53.3% | 22.87 | +3.3% | +6.0% | -1.4% | -1.8% | +2.2% | -6.8% | — |
| May 15, 2023 | AMC | -0.16 | -0.53 | -230.9% | 23.19 | -0.8% | +9.5% | -2.8% | +3.2% | +3.5% | -4.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $2.54 | $2.40 | -5.5% | -5.5% | +3.3% | -2.4% | +9.5% | -0.8% |
| May 8 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $2.32 | $2.35 | +1.3% | +22.8% | +3.9% | -6.1% | -10.8% | -3.2% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.08 | $3.00 | -2.6% | -12.3% | -3.7% | -2.3% | -1.6% | -4.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.89 | $3.50 | -10.0% | -12.6% | -5.9% | -5.3% | +1.7% | -12.3% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.94 | $2.94 | +0.0% | -19.7% | +11.4% | -5.7% | +0.4% | -1.2% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.09 | $2.18 | +4.3% | +1.9% | -5.2% | +3.5% | -2.4% | +0.5% |
| Jun 3 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $2.71 | $2.75 | +1.5% | +3.7% | -8.5% | +0.8% | -2.7% | -9.5% |
| May 31 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $2.65 | $2.70 | +1.9% | +2.3% | +3.7% | -8.5% | +0.8% | -2.7% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.83 | $3.89 | +1.6% | -5.7% | -0.8% | +1.7% | -1.1% | +1.4% |
| Apr 3 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $5.25 | $5.25 | +0.0% | -7.4% | -2.7% | +4.2% | -5.3% | -1.5% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.24 | $5.19 | -1.0% | +0.2% | -7.4% | -2.7% | +4.2% | -5.3% |
| Nov 24 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $11.19 | $11.29 | +0.9% | -0.8% | -2.1% | -3.8% | +11.9% | +1.7% |
| Jun 9 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $28.40 | $28.98 | +2.0% | -2.0% | +7.6% | +6.8% | +6.4% | +6.2% |
| May 18 | Brookline Capital | Maintains | Hold → Hold | — | $24.70 | $24.48 | -0.9% | +3.2% | +3.5% | -4.9% | -3.5% | -3.9% |
| Feb 15 | Benchmark | Maintains | Speculative Buy → Buy | — | $5.99 | $6.01 | +0.3% | +7.6% | -3.8% | +6.0% | +13.3% | +16.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Smalling RalphOff | Head of Regulatory | Sell | 192 | $2.93 | $563 | 67,611 | -4.87% | +0.70% |
| Jun 1, 2026 | Thomas JohnDir | — | Sell | 10,000 | $2.98 | $30K | 472,784 | +1.69% | +1.71% |
| May 11, 2026 | Zindrick ThomasOff | President and CEO | Sell | 2,798 | $2.94 | $8K | 532,051 | +7.41% | -1.75% |
| May 11, 2026 | Cappello JosephOff | Chief Technical Officer | Sell | 605 | $2.97 | $2K | 154,549 | +7.41% | -1.75% |
| May 11, 2026 | Smalling RalphOff | Head of Regulatory | Sell | 270 | $2.98 | $804 | 67,803 | +7.41% | -1.75% |
| May 11, 2026 | Yu YongOff | Chief Scientific Officer | Sell | 605 | $2.97 | $2K | 149,706 | +7.41% | -1.75% |
8-K
Genelux Corporation -- 8-K Filing
Jun 22
8-K
Unknown — 8-K Filing
Greenlink Technologies is raising capital through a stock offering to fund research and operations, diluting existing shareholders while providing financial flexibility for business development.
Mar 19
8-K · 7.01
! Medium
Genelux Corporation -- 8-K 7.01: Regulation FD Disclosure
Genelux Corporation updated its investor presentation with business and strategic updates on February 2, 2026, making new information available to shareholders via its investor relations website.
Feb 2
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Small Cap Core Fund | 25,185 | $61K | Mar 2026 |
| 2 | Innovator U.S. Small Cap Managed Floor ETF | 2,895 | $8K | Jan 2026 |
Valuation
Market Cap
$107.8M
Enterprise Value
$94.5M
P/E (TTM)
-3.30x
Forward P/E
—
PEG Ratio
0.53x
P/B
9.34x
P/S
13476.49x
P/FCF
-4.09x
EV/EBITDA
—
Shares Out
37.2M
Financials (TTM)
Revenue
$8K
Net Income
-$31.8M
EBITDA
-$32.0M
Free Cash Flow
-$26.4M
Op Cash Flow
-$25.3M
EPS Basic
$-0.86
EPS Diluted
$-0.88
EPS Forward
$-0.82
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$19.0M
Total Liab.
$7.5M
Total Equity
$11.5M
Cash
$14.6M
LT Debt
$1.3M
Book Value/Sh
$0.31
Debt/Equity
0.15x
Current Ratio
2.43
Quick Ratio
2.43
Returns & Growth
ROE
-278.5%
ROA
-168.9%
ROIC
-251.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+9.5%
Price Returns
2W
-0.3%
1M
+1.3%
3M
+17.6%
6M
-33.8%
12M
+6.4%
Technicals
52W High
$8.24
52W Low
$2.30
50d MA
$2.88
200d MA
$3.70
RSI (14)
52.20
ATR (14)
$0.18
Beta
0.46
Avg Volume
175K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$17.33
High
$20.00
Low
$16.00
Median
$16.00
Data updated apr 25, 2026 11:51am
· Source: financialmodelingprep.com